Skip to main content

Table 1 Hybridoma response to amino- and carboxy-terminal truncated peptides of HC gp-39(263–275)

From: Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263–275) epitope: an MHC anchor variant peptide for immune modulation

     Hybridoma response (SI)
Compound HC gp-39 Sequence HLA-DR binding IC50 (μM) 5G11 8B12 14G11 20H5
     Vβ10b Vβ10b Vβ6 Vβ10b
1 263–275 RSFTLASSETGVG 0.12 13 9 15 26
2 263–274 RSFTLASSETGV  0.09 7 8 10 22
3 263–273 RSFTLASSETG   0.20 2 5 5 15
4 263–272 RSFTLASSET    7.0 1 1 1 2
5 264–275  SFTLASSETGVG 0.09 12 10 15 27
6 265–275   FTLASSETGVG 0.11 11 6 8 24
7 266–275    TLASSETGVG >100 1 1 1 5
8 267–275     LASSETGVG >100 1 1 1 1
9 264–274  SFTLASSETGV  0.12 ND 7 13 22
  1. Binding of peptides to HLA-DR4(B1*0401) was determined in a competition binding assay. IC50 = 50% inhibitory concentration. IC50 < 1 μM = high affinity binder; IC50 between 1 and 10 μM = good binder; IC50 between 10 and 100 μM = intermediate binder; IC50 between 100 and 1,000 μM = poor binder. The decimals do not reflect the accuracy of the data but represent the calculated geometric means obtained in two experiments. The HLA-DRB1*0401 expressing B lymphoblastoid cell line was used as a source of antigen-presenting cells. Background values for hybridomas 5G11, 8B12, 14G11 and 20H5 were 8,147, 7,470, 8,598 and 35,749 mean fluorescence units/counts, respectively. Hybridoma IL-2 response is expressed as stimulation index (SI) calculated as the ratio of mean fluorescence counts of antigen-stimulated cultures and control cultures. Values in bold are considered positive (SI > 2). Data are representative of at least three independent experiments. ND, not determined.